Nephros, Inc. (NEPH)
USD 1.48
(-3.9%)
USD 1.48
(-3.9%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.47 Million USD | -21.66% |
| 2022 | 3.15 Million USD | -34.24% |
| 2021 | 4.79 Million USD | -9.6% |
| 2020 | 5.3 Million USD | 107.03% |
| 2019 | 2.56 Million USD | 37.45% |
| 2018 | 1.86 Million USD | 176.56% |
| 2017 | 674 Thousand USD | 40.71% |
| 2016 | 479 Thousand USD | -18.95% |
| 2015 | 591 Thousand USD | 217.74% |
| 2014 | 186 Thousand USD | 14.81% |
| 2013 | 162 Thousand USD | -48.08% |
| 2012 | 312 Thousand USD | 26.32% |
| 2011 | 247 Thousand USD | -65.98% |
| 2010 | 726 Thousand USD | 11.18% |
| 2009 | 653 Thousand USD | -9.81% |
| 2008 | 724 Thousand USD | 115.48% |
| 2007 | 336 Thousand USD | -34.34% |
| 2006 | 511.71 Thousand USD | -37.18% |
| 2005 | 814.54 Thousand USD | 24.67% |
| 2004 | 653.35 Thousand USD | 223.5% |
| 2003 | 201.96 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 2.8 Million USD | 0.86% |
| 2024 Q1 | 2.77 Million USD | 12.51% |
| 2023 Q3 | 2.26 Million USD | 6.68% |
| 2023 Q2 | 2.12 Million USD | -9.45% |
| 2023 Q1 | 2.34 Million USD | -25.53% |
| 2023 FY | 2.47 Million USD | -21.66% |
| 2023 Q4 | 2.47 Million USD | 8.91% |
| 2022 Q1 | 4.67 Million USD | -2.42% |
| 2022 Q3 | 3.48 Million USD | -25.21% |
| 2022 Q4 | 3.15 Million USD | -9.6% |
| 2022 FY | 3.15 Million USD | -34.24% |
| 2022 Q2 | 4.66 Million USD | -0.32% |
| 2021 FY | 4.79 Million USD | -9.6% |
| 2021 Q2 | 5.08 Million USD | 8.72% |
| 2021 Q3 | 4.64 Million USD | -8.61% |
| 2021 Q4 | 4.79 Million USD | 3.14% |
| 2021 Q1 | 4.67 Million USD | -11.78% |
| 2020 Q3 | 5.38 Million USD | 12.92% |
| 2020 Q1 | 3.64 Million USD | 42.43% |
| 2020 Q2 | 4.76 Million USD | 30.69% |
| 2020 Q4 | 5.3 Million USD | -1.5% |
| 2020 FY | 5.3 Million USD | 107.03% |
| 2019 Q2 | 2.31 Million USD | 13.43% |
| 2019 FY | 2.56 Million USD | 37.45% |
| 2019 Q3 | 2.12 Million USD | -8.04% |
| 2019 Q4 | 2.56 Million USD | 20.39% |
| 2019 Q1 | 2.04 Million USD | 9.44% |
| 2018 Q1 | 928 Thousand USD | 37.69% |
| 2018 Q4 | 1.86 Million USD | 27.76% |
| 2018 FY | 1.86 Million USD | 176.56% |
| 2018 Q2 | 1.35 Million USD | 45.69% |
| 2018 Q3 | 1.45 Million USD | 7.91% |
| 2017 Q3 | 581 Thousand USD | -3.65% |
| 2017 Q2 | 603 Thousand USD | 50.37% |
| 2017 Q4 | 674 Thousand USD | 16.01% |
| 2017 FY | 674 Thousand USD | 40.71% |
| 2017 Q1 | 401 Thousand USD | -16.28% |
| 2016 Q1 | 476 Thousand USD | -19.46% |
| 2016 Q3 | 341 Thousand USD | -17.43% |
| 2016 Q2 | 413 Thousand USD | -13.24% |
| 2016 FY | 479 Thousand USD | -18.95% |
| 2016 Q4 | 479 Thousand USD | 40.47% |
| 2015 Q2 | 419 Thousand USD | 101.44% |
| 2015 FY | 591 Thousand USD | 217.74% |
| 2015 Q1 | 208 Thousand USD | 11.83% |
| 2015 Q4 | 591 Thousand USD | -11.13% |
| 2015 Q3 | 665 Thousand USD | 58.71% |
| 2014 Q4 | 186 Thousand USD | 72.22% |
| 2014 Q2 | 163 Thousand USD | -15.1% |
| 2014 Q1 | 192 Thousand USD | 18.52% |
| 2014 FY | 186 Thousand USD | 14.81% |
| 2014 Q3 | 108 Thousand USD | -33.74% |
| 2013 Q4 | 162 Thousand USD | -44.33% |
| 2013 Q3 | 291 Thousand USD | 97.96% |
| 2013 FY | 162 Thousand USD | -48.08% |
| 2013 Q2 | 147 Thousand USD | -22.22% |
| 2013 Q1 | 189 Thousand USD | -39.42% |
| 2012 Q2 | 268 Thousand USD | 11.67% |
| 2012 Q3 | 293 Thousand USD | 9.33% |
| 2012 Q4 | 312 Thousand USD | 6.48% |
| 2012 Q1 | 240 Thousand USD | -2.83% |
| 2012 FY | 312 Thousand USD | 26.32% |
| 2011 Q3 | 396 Thousand USD | 18.56% |
| 2011 Q1 | 624 Thousand USD | -14.05% |
| 2011 Q2 | 334 Thousand USD | -46.47% |
| 2011 FY | 247 Thousand USD | -65.98% |
| 2011 Q4 | 247 Thousand USD | -37.63% |
| 2010 Q2 | 697 Thousand USD | -11.32% |
| 2010 Q1 | 786 Thousand USD | 20.37% |
| 2010 FY | 726 Thousand USD | 11.18% |
| 2010 Q4 | 726 Thousand USD | 19.41% |
| 2010 Q3 | 608 Thousand USD | -12.77% |
| 2009 FY | 653 Thousand USD | -9.81% |
| 2009 Q3 | 607 Thousand USD | -20.86% |
| 2009 Q1 | 589 Thousand USD | -18.65% |
| 2009 Q2 | 767 Thousand USD | 30.22% |
| 2009 Q4 | 653 Thousand USD | 7.58% |
| 2008 FY | 724 Thousand USD | 115.48% |
| 2008 Q4 | 724 Thousand USD | 114.84% |
| 2008 Q3 | 337 Thousand USD | -20.14% |
| 2008 Q2 | 422 Thousand USD | 18.87% |
| 2008 Q1 | 355 Thousand USD | 5.65% |
| 2007 Q3 | 560 Thousand USD | -11.67% |
| 2007 Q4 | 336 Thousand USD | -40.0% |
| 2007 Q1 | 656 Thousand USD | 28.2% |
| 2007 Q2 | 634 Thousand USD | -3.35% |
| 2007 FY | 336 Thousand USD | -34.34% |
| 2006 Q3 | 463.44 Thousand USD | -2.47% |
| 2006 Q4 | 511.71 Thousand USD | 10.42% |
| 2006 FY | 511.71 Thousand USD | -37.18% |
| 2006 Q1 | 903.06 Thousand USD | 10.87% |
| 2006 Q2 | 475.17 Thousand USD | -47.38% |
| 2005 Q3 | 468.9 Thousand USD | -11.21% |
| 2005 Q2 | 528.12 Thousand USD | -10.01% |
| 2005 FY | 814.54 Thousand USD | 24.67% |
| 2005 Q1 | 586.87 Thousand USD | -10.17% |
| 2005 Q4 | 814.54 Thousand USD | 73.71% |
| 2004 Q4 | 653.35 Thousand USD | 93.75% |
| 2004 FY | 653.35 Thousand USD | 223.5% |
| 2004 Q2 | 103.16 Thousand USD | 0.0% |
| 2004 Q3 | 337.21 Thousand USD | 226.87% |
| 2003 FY | 201.96 Thousand USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 17.87 Million USD | 86.183% |
| AngioDynamics, Inc. | 60.61 Million USD | 95.925% |
| AtriCure, Inc. | 67.89 Million USD | 96.362% |
| Avinger, Inc. | 5.29 Million USD | 53.379% |
| Azenta, Inc. | 128.19 Million USD | 98.073% |
| BioLife Solutions, Inc. | 43.45 Million USD | 94.316% |
| The Cooper Companies, Inc. | 735.6 Million USD | 99.664% |
| Daxor Corporation | - USD | -Infinity% |
| Ekso Bionics Holdings, Inc. | 5.05 Million USD | 51.089% |
| Femasys Inc. | 667.11 Thousand USD | -270.249% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 24.71 Million USD | 90.006% |
| Hologic, Inc. | 679.8 Million USD | 99.637% |
| ICU Medical, Inc. | 709.36 Million USD | 99.652% |
| Intuitive Surgical, Inc. | 1.22 Billion USD | 99.798% |
| KORU Medical Systems, Inc. | 3.48 Million USD | 29.05% |
| LeMaitre Vascular, Inc. | 52.33 Million USD | 95.28% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -188.296% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -188.296% |
| Masimo Corporation | 545 Million USD | 99.547% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 1.61 Million USD | -52.731% |
| Merit Medical Systems, Inc. | 303.87 Million USD | 99.187% |
| NovoCure Limited | 38.15 Million USD | 93.526% |
| NEXGEL, Inc. | 1.31 Million USD | -87.263% |
| NEXGEL, Inc. | 1.31 Million USD | -87.263% |
| Singular Genomics Systems, Inc. | 13.57 Million USD | 81.801% |
| OraSure Technologies, Inc. | 47.61 Million USD | 94.812% |
| Pro-Dex, Inc. | 15.26 Million USD | 83.823% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 494.37 Thousand USD | -399.622% |
| Precision Optics Corporation, Inc. | 2.86 Million USD | 13.88% |
| QuidelOrtho Corporation | 577.8 Million USD | 99.573% |
| Repligen Corporation | 202.32 Million USD | 98.779% |
| Sanara MedTech Inc. | 4.71 Million USD | 47.642% |
| STAAR Surgical Company | 35.13 Million USD | 92.969% |
| Sharps Technology, Inc. | 1.7 Million USD | -44.518% |
| Utah Medical Products, Inc. | 9.58 Million USD | 74.223% |
| DENTSPLY SIRONA Inc. | 624 Million USD | 99.604% |
| Jin Medical International Ltd. | 5.05 Million USD | 51.119% |